Impaired function of antibodies to pneumococcal surface protein A but Not to capsular polysaccharide in Mexican American adults with type 2 diabetes mellitus

Clinical and Vaccine Immunology

Volumn 19, Issue 9, 2012, Pages 1360-1369

  Mathews, Christine E ^a   Brown, Eric L ^b   Martinez, Perla J ^a   Bagaria, Upasana ^c   Nahm, Moon H ^d   Burton, Robert L ^d   Fisher Hoch, Susan P ^a   McCormick, Joseph B ^a   Mirza, Shaper ^a  

^a UNIVERSITY OF TEXAS AT BROWNSVILLE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCAL SURFACE PROTEIN A; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISPANIC; HUMAN; HYPERGLYCEMIA; IMMUNE DYSREGULATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPSONIZATION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT SYSTEM PROTEINS; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MEXICAN AMERICANS; MIDDLE AGED; OPSONIN PROTEINS; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE;

EID: 84865972958     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00268-12     Document Type: Article

References (50)

1. American Diabetes Association. 2010. Standards of medical care in diabetes - 2010. Diabetes Care 33(Suppl 1):S11-S61.
2. American Diabetes Association. 2006. Standard of medical care in diabetes - 2006. Diabetes Care 29(Suppl 1):S4 -S42.
3. + T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect. Immun. 75: 5460-5464.
4. Beam TR, Jr, Crigler ED, Goldman JK, Schiffman G. 1980. Antibody response to polyvalent pneumococcal polysaccharide vaccine in diabetics. JAMA 244:2621-2624. (Pubitemid 11192750)
5. Bertoni AG, Saydah S, Brancati FL. 2001. Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care 24:1044-1049. (Pubitemid 33716374)
6. Bolan G, et al. 1986. Pneumococcal vaccine efficacy in selected populations in the United States. Ann. Intern. Med. 104:1-6. (Pubitemid 16182764)
7. Briles DE, Swiatlo E, Edwards K. 2000. Vaccine strategies for Streptococcus pneumoniae, p 419-433. In Stevens DL, Kaplan EL (ed), Streptococcal infections. Oxford, New York, NY.
8. Burton RL, Nahm MH. 2006. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin. Vaccine Immunol. 13:1004-1009. (Pubitemid 44518968)
9. Chavakis T, Bierhaus A, Nawroth PP. 2004. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect. 6:1219-1225. (Pubitemid 39370091)
10. Daniels CC, et al. 2010. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect. Immun. 78:2163-2172.
11. Dave S, Brooks-Walter A, Pangburn MK, McDaniel LS. 2001. PspC, a pneumococcal surface protein, binds human factor H. Infect. Immun. 69:3435-3437. (Pubitemid 32332245)
12. Douglas RM, Miles HB. 1984. Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. J. Infect. Dis. 149:861-869. (Pubitemid 14082146)
13. Ekdahl K, Braconier JH, Svanborg C. 1997. Immunoglobulin deficiencies and impaired immune response to polysaccharide antigens in adult patients with recurrent community-acquired pneumonia. Scand. J. Infect. Dis. 29:401-407.
14. Fabrizi F, V Dixit, P Martin, P Messa. 2011. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment. Pharmacol. Ther. 33:815-821.
15. Fisher-Hoch SP, et al. 2010. Socioeconomic status and prevalence of obesity and diabetes in a Mexican American community, Cameron County, Texas, 2004-2007. Prev. Chronic Dis. 7:A53.
16. Forrester HL, Jahnigen DW, LaForce FM. 1987. Inefficacy of pneumococcal vaccine in a high-risk population. Am. J. Med. 83:425-430.
17. (a)Freijd A, Hammarström L, Persson MA, Smith CI. 1984. Plasma anti-pneumococcal antibody activity of the IgG class and subclasses in otitis prone children. Clin. Exp. Immunol. 56:233-238.
18. Grundy SM, Brewer HB, Jr, Cleeman JI, Smith SC, Jr., Lenfant C. 2004. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 109:433-438. (Pubitemid 38133916)
19. Holmlund E, Quiambao B, Ollgren J, Nohynek H, Kayhty H. 2006. Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage. Vaccine 24:57-65. (Pubitemid 41721100)
20. Jackson LA, Janoff EN. 2008. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin. Infect. Dis. 47:1328-1338.
21. Kadioglu A, Weiser JN, Paton JC, Andrew PW. 2008. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat. Rev. Microbiol. 6:288-301. (Pubitemid 351404773)
22. Koivula I, Sten M, Leinonen M, Makela PH. 1997. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population- based trial. Am. J. Med. 103:281-290. (Pubitemid 27459254)
23. Kornum JB, et al. 2008. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care 31:1541-1545.
24. Kornum JB, et al. 2007. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care 30:2251-2257. (Pubitemid 47359027)
25. Koziel H, Koziel MJ. 1995. Pulmonary complications of diabetes mellitus. Pneumonia. Infect. Dis. Clin. North Am. 9:65-96.
26. Lahiri T, Waltz DA. 2001. Preimmunization anti-pneumococcal antibody levels are protective in a majority of patients with cystic fibrosis. Pediatrics 108:E62. doi:10.1542/peds.108.4.e62.
27. Lapolla A, et al. 2000. Matrix-assisted laser desorption/ionization mass spectrometry, enzymatic digestion, and molecular modeling in the study of nonenzymatic glycation of IgG. J. Am. Soc. Mass Spectrom. 11:153-159. (Pubitemid 34506433)
28. Lapolla A, et al. 1999. Evaluation of glycated globins by matrix-assisted laser desorption/ionization mass spectrometry. Clin. Chem. 45:288-290. (Pubitemid 29079131)
29. Lederman MM, Rodman HM, Schacter BZ, Jones PK, Schiffman G. 1982. Antibody response to pneumococcal polysaccharides in insulindependent diabetes mellitus. Diabetes Care 5:36-39. (Pubitemid 12212119)
30. Lee LY, et al. 2004. Inhibition of complement activation by a secreted Staphylococcus aureus protein. J. Infect. Dis. 190:571-579. (Pubitemid 38982098)
31. Malley, R. 2010. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J. Mol. Med. (Berl.) 88:135-142.
32. Malley R, et al. 2007. Serum antipneumococcal antibodies and pneumococcal colonization in adults with chronic obstructive pulmonary disease. J. Infect. Dis. 196:928 -935.
33. Malley R, et al. 2005. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc. Natl. Acad. Sci. U. S. A. 102:4848-4853. (Pubitemid 40471542)
34. McCool TL, Cate TR, Moy G, Weiser JN. 2002. The immune response to pneumococcal proteins during experimental human carriage. J. Exp. Med. 195:359-365. (Pubitemid 34461494)
35. Melegaro A, Edmunds WJ. 2004. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur. J. Epidemiol. 19:353-363. (Pubitemid 39005435)
36. Melegaro A, Edmunds WJ. 2004. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur. J. Epidemiol. 19:365-375. (Pubitemid 39005436)
37. Nam JS, et al. 2011. The humoral immune response to the inactivated influenza A (H1N1) monovalent vaccine in patients with type 2 diabetes mellitus in Korea. Diabet. Med. 28:815-817.
38. Nikolajczyk BS, Jagannathan-Bogdan M, Shin H, Gyurko R. 2011. State of the union between metabolism and the immune system in type 2 diabetes. Genes Immun. 12:239-250.
39. Omori K, et al. 2008. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase. J. Leukoc. Biol. 84:292-301. (Pubitemid 351960304)
40. Peleg AY, Weerarathna T, McCarthy JS, Davis TM. 2007. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab. Res. Rev. 23:3-13. (Pubitemid 46152480)
41. Rapola S, et al. 2000. Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J. Infect. Dis. 182:1146-1152.
42. Ren B, et al. 2004. The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection. J. Immunol. 173: 7506-7512. (Pubitemid 39628191)
43. Schenkein JG, Park S, Nahm MH. 2008. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 26:5521-5526.
44. Shah BR, Hux JE. 2003. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 26:510-513. (Pubitemid 36929083)
45. Shapiro ED, et al. 1991. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325:1453-1460.
46. Smith SA, Poland GA. 2000. Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care 23:95-108. (Pubitemid 30022903)
47. Thomsen RW, et al. 2004. Risk of community-acquired pneumococcal bacteremia in patients with diabetes: a population-based case-control study. Diabetes Care 27:1143-1147. (Pubitemid 38579780)
48. Thomsen RW, et al. 2004. Diabetes and outcome of community-acquired pneumococcal bacteremia: a 10-year population-based cohort study. Diabetes Care 27:70-76. (Pubitemid 38196712)
49. Virolainen A, Russell W, Rapola S, Briles DE, Käythy H. 1996. Human antibodies to pneumococcal surface protein A (PspA), abstr. 150. Abstr. 36th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
50. Wernette CM, et al. 2003. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin. Diagn. Lab. Immunol. 10:514-519. (Pubitemid 36890430)